LY2780301

DRUG2 trials

Sponsors

Eli Lilly and Company, Gustave Roussy, Cancer Campus, Grand Paris

Conditions

Metastases, NeoplasmSolid Tumors and Non-Hodgkin's Lymphoma

Phase 1

A Study in Patients With Advanced or Metastatic Cancer

CompletedNCT01115751

Eli Lilly and CompanyMetastases, Neoplasm

Start: 2010-03-31End: 2012-07-31Target: 80Updated: 2012-07-31

A Phase Ib Study of the Safety, Tolerability and Efficacy of LY2780301 in Combination With Gemcitabine

CompletedNCT02018874

Gustave Roussy, Cancer Campus, Grand ParisSolid Tumors and Non-Hodgkin's Lymphoma

Start: 2013-09-30End: 2016-04-30Updated: 2016-07-12

Related Papers

Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study.

2017-07-2413 citations